CCL17

Across TCGA pan-cancer cohorts, CCL17 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CCL17 data layer.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CCL17 RNA is associated with better overall survival. In most high-consensus cancer types, elevated CCL17 expression acts as an unfavorable survival marker, although some lineages such as CESC and BLCA show a favorable association.

CESC, BLCA, and HNSC are the cancer types where CCL17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.931	0.812	<.001	118	view →
BLCA	DFS	Median	All	0.679	0.551	.001	94	view →
HNSC	DFS	Tertile	III,IV	0.772	0.607	.002	72	view →
UCEC	OS	Quartile	All	0.940	0.847	.003	30	view →
CHOL	OS	Median	III,IV	1.000	0.286	.008	27	view →
SKCM	DFS	Quartile	All	0.858	0.645	.002	22	view →
SARC	OS	Tertile	All	0.645	0.337	.001	22	view →
OV	DFS	Quartile	II,III,IV	0.641	0.509	.012	16	view →
KIRC	DFS	Tertile	IV	0.748	0.331	<.001	16	view →
LUAD	DFS	Median	All	0.834	0.745	.007	13	view →
LUSC	DFS	Quartile	III,IV	0.759	0.385	.013	12	view →
DLBC	DFS	Tertile	IV	1.000	0.240	.008	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CCL17–CESC (OS)

Open the CESC breakdown →